Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

Launched by CENTRE HOSPITALIER DE SAINT-DENIS · Jun 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the best way to treat a serious lung infection called pneumonia in patients who are very sick and on breathing machines in the intensive care unit (ICU). The pneumonia in this study is caused by a specific type of bacteria called Stenotrophomonas maltophilia, which can be hard to treat because it often resists common antibiotics. The researchers are comparing whether using one antibiotic or two antibiotics works better, and whether treating the infection for 7 days or 14 days leads to better outcomes, such as helping patients survive and preventing the infection from coming back.

Adults who are 18 years or older, currently or previously treated in a medical ICU, who are on a breathing machine and have pneumonia caused by this bacteria may be eligible to participate. If you join the study, your doctors will carefully monitor your treatment to see which antibiotic approach helps you recover best. The study is also looking at how the bacteria respond to antibiotics and how often patients get pneumonia again. This research aims to find clearer answers about the most effective and safest way to treat this challenging infection in critically ill patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (age ≥ 18 years)
• • Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023
• • Intubated and mechanically ventilated
• • Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia
• Exclusion Criteria:
• • Patients under 18 years old
• • Patients who refuse the use of their data for research purposes